IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

Fast Dissolving Tablets: Unveiling Emerging Trends and Pioneering Innovative Approaches for Enhanced Patient Experience and Therapeutic Efficacy

Mr. Mangesh Shrirang Mohite[1], Prof. Unmesh M. Joshi[2], Dr. K. R Biyani[3]
Anuradha College of Pharmacy, Chikhli, Buldana, Maharashtra, India
mangeshmohite555@gmail.com

Abstract: *Fast Dissolving Tablets (FDTs) represent a revolutionary advancement in drug delivery, offering rapid disintegration, enhanced bioavailability, and improved patient compliance. This review explores the multifaceted landscape of FDT development, encompassing formulation strategies, manufacturing techniques, novel drug delivery systems, and their potential implications for patient-centered pharmaceutical design. The role of interdisciplinary collaborations among pharmaceutical scientists, material engineers, and formulation experts is highlighted, showcasing how their combined expertise shapes the design and optimization of FDTs. FDTs hold particular promise in personalized medicine, enabling tailored dosing regimens and facilitating precision therapies. Integration into telemedicine and digital health platforms further enhances patient-centric care, while the potential of FDTs in addressing challenges within pediatric, geriatric, and neurologic populations underscores their versatility. As FDTs continue to evolve, driven by cutting-edge research and innovation, they offer a glimpse into a future where medication administration is convenient, effective, and aligned with individual patient needs. This review underscores the transformative potential of FDTs in shaping the landscape of modern pharmaceutical design and advancing patient outcomes.*

Keywords: Fast Dissolving Tablets, Drug Delivery, Patient Compliance, Personalized Medicine, Interdisciplinary Collaboration, Pharmaceutical Innovation

I. INTRODUCTION

Background on Fast Dissolving Tablets

Fast Dissolving Tablets (FDTs) have emerged as a notable advancement in pharmaceutical technology. [1,2] These tablets are designed to disintegrate and dissolve rapidly in the oral cavity, without the need for additional water or chewing. The formulation of FDTs involves a combination of innovative techniques and excipients, allowing for their rapid dissolution and absorption. This advancement addresses the limitations of conventional tablet formulations that require swallowing and water intake. [2,3] FDTs offer a convenient and patient-friendly alternative, particularly beneficial for individuals who have difficulty swallowing traditional tablets or who are on the go.[4]

Importance of Rapid Drug Disintegration and Enhanced Patient Experience

The rapid disintegration and dissolution of FDTs hold significant importance in modern healthcare.[5]Patients, especially those with dysphagia, pediatric or geriatric populations, and individuals with restricted access to water, often encounter challenges when it comes to swallowing conventional tablets or capsules. FDTs alleviate these challenges by providing a seamless experience, improving medication compliance, and ultimately enhancing the overall patient experience.[6,7] The ability of FDTs to bypass the gastrointestinal tract and enter systemic circulation more rapidly can also lead to quicker onset of action, which is particularly crucial for drugs intended for pain relief, allergies, or other conditions requiring prompt symptom relief.[8,9]

Objectives of the Review

The primary objectives of this review are to comprehensively explore the various aspects of Fast Dissolving Tablets, including their formulation techniques, mechanisms of disintegration and dissolution, impact on drug delivery and

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

bioavailability, and potential therapeutic applications. Additionally, the review aims to critically analyze the advantages and limitations of FDTs in comparison to traditional oral dosage forms. By synthesizing current research and studies, this review seeks to provide healthcare practitioners, researchers, and pharmaceutical manufacturers with a comprehensive understanding of the potential of FDTs to revolutionize drug delivery and patient care.

In summary, this paper delves into the dynamic realm of Fast Dissolving Tablets, shedding light on their formulation, mechanisms, benefits, and potential impact on patient well-being. By addressing the need for patient-centric pharmaceutical innovations, FDTs stand as a prime example of the industry's dedication to optimizing drug delivery methods for enhanced therapeutic outcomes.

II. FORMULATION STRATEGIES FOR FAST DISSOLVING TABLETS

Role of Superdisintegrants

Superdisintegrants play a pivotal role in the formulation of Fast Dissolving Tablets (FDTs). These are substances that facilitate the rapid disintegration of tablets upon contact with moisture, promoting quick drug release and subsequent dissolution. Commonly used superdisintegrants include croscarmellose sodium, crospovidone, sodium starch glycolate, and low-substituted hydroxypropyl cellulose. These materials possess the ability to swell and create channels within the tablet matrix, allowing water penetration and resulting in the fragmentation of tablets into fine particles. The presence of superdisintegrants in FDT formulations significantly reduces the disintegration time, thereby enhancing the overall patient experience and ensuring efficient drug delivery. [10-15]

Novel Excipients for Rapid Drug Release

In addition to superdisintegrants, novel excipients have been explored to achieve rapid drug release in Fast Dissolving Tablets. For instance, the use of effervescent agents, which release carbon dioxide upon contact with water, creates a fizzing effect that aids in tablet disintegration. Moreover, the incorporation of porous materials, such as porous silicates or modified forms of starch, contributes to improved tablet wettability and faster dissolution rates. These innovative excipients not only enhance the mechanical properties of the tablet but also contribute to the overall effectiveness of drug delivery. [16-18]

Approaches to Enhance Tablet Porosity

Enhancing tablet porosity is a crucial strategy in the formulation of FDTs. Increased tablet porosity facilitates faster water uptake and, consequently, quicker disintegration and dissolution. Techniques such as direct compression, sublimation, and spray drying have been employed to create porous structures within the tablet matrix. Additionally, freeze-drying, commonly used for heat-sensitive drugs, results in a highly porous structure that allows rapid disintegration. The incorporation of these approaches ensures efficient drug dispersion upon contact with saliva, leading to enhanced bioavailability and therapeutic outcomes.[19-23]

Combination of Disintegration Methods

Combining multiple disintegration methods is an emerging approach to optimize the formulation of Fast Dissolving Tablets. By synergistically utilizing various mechanisms, such as superdisintegrants, effervescent agents, and porous materials, formulation scientists can achieve ultra-rapid disintegration and dissolution profiles. This approach not only ensures consistent and reliable performance of FDTs but also enables customization based on the specific drug properties and therapeutic requirements. The combination of disintegration methods opens the door to tailoring FDT formulations for a wide range of drugs, further expanding their applicability and impact in patient care. [24-29]

III. MANUFACTURING TECHNIQUES AND TECHNOLOGIES

Direct Compression Method

The direct compression method stands as one of the most straightforward and widely employed techniques for manufacturing Fast Dissolving Tablets (FDTs). This method involves blending the active pharmaceutical ingredient (API) with suitable excipients, including superdisintegrants and diluents, followed by compression into tablet form. The simplicity and cost-effectiveness of direct compression make it an attractive choice for large-scale production of FDTs.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

The technique offers precise control over the formulation components, allowing for customization of tablet properties, such as disintegration time and dissolution rate. However, careful consideration of the flow and compression properties of the formulation ingredients is essential to ensure uniform tablet quality. [30-36]

Lyophilization or Freeze-Drying

Lyophilization, commonly known as freeze-drying, is a specialized manufacturing technique utilized for the production of delicate or heat-sensitive drugs in Fast Dissolving Tablets. In this process, the tablet formulation is frozen and then subjected to a vacuum environment to remove moisture via sublimation. The result is a highly porous and rapidly disintegrating tablet structure. Lyophilization not only preserves the stability of sensitive drugs but also creates a unique porous matrix that enhances the tablet's disintegration and dissolution properties. While more complex and resource-intensive than direct compression, lyophilization offers advantages in terms of product stability and bioavailability, making it a valuable option for certain formulations. [37-39]

Molding Techniques (e.g., ODT Films)

Molding techniques, particularly the production of Orally Disintegrating Films (ODTs), have gained significant attention in the realm of Fast Dissolving Tablets. ODT films are thin, flexible sheets that contain the active drug and rapidly disintegrate upon contact with saliva. The manufacturing process involves creating a solution or dispersion of the drug and excipients, which is then cast onto a substrate and dried to form a film. ODT films offer precise dosing, ease of administration, and rapid disintegration, making them an excellent alternative for patients who have difficulty swallowing or prefer a more discreet dosage form. Additionally, the flexibility of ODT films allows for taste masking and incorporation of multiple APIs, opening doors to innovative combination therapies. [40-41]

3D Printing for Customized Dosage Forms

The advent of 3D printing has revolutionized pharmaceutical manufacturing, enabling the creation of customized Fast Dissolving Tablets with intricate designs and tailored drug release profiles. 3D printing technology allows for precise layer-by-layer deposition of formulation materials, resulting in tablets with controlled porosity and disintegration properties. This approach is particularly valuable for personalized medicine, where dosage forms can be tailored to individual patient needs, combining multiple drugs or altering release kinetics. While still in its nascent stages for pharmaceutical applications, 3D printing holds immense potential to reshape the landscape of Fast Dissolving Tablet manufacturing, offering unprecedented flexibility and adaptability. [42-43]

IV. NOVEL DRUG DELIVERY SYSTEMS FOR FAST DISSOLVING TABLETS

Nanostructured Lipid Carriers (NLCs) and Solid Lipid Nanoparticles (SLNs)

Nanostructured Lipid Carriers (NLCs) and Solid Lipid Nanoparticles (SLNs) represent advanced drug delivery systems that have gained prominence in the formulation of Fast Dissolving Tablets (FDTs). These systems involve the encapsulation of hydrophobic drugs within lipid matrices, offering enhanced drug solubility, stability, and bioavailability. The incorporation of NLCs or SLNs into FDTs not only improves the drug's dissolution and absorption but also contributes to the rapid disintegration of the tablet due to the lipid's amphiphilic nature. The lipid nanoparticles provide a reservoir of the drug, facilitating sustained release and potentially minimizing the frequency of dosing. Furthermore, their compatibility with the FDT formulation process opens avenues for synergistic enhancement of drug delivery and patient experience. [42-43]

Cyclodextrin Complexation

Cyclodextrins, cyclic oligosaccharides with a hydrophobic cavity, have emerged as versatile excipients for enhancing drug solubility and bioavailability in Fast Dissolving Tablets. Through complexation, hydrophobic drug molecules are encapsulated within the cyclodextrin cavity, forming inclusion complexes that improve drug wettability and dissolution. The resultant increase in drug surface area upon disintegration accelerates dissolution rates, contributing to the rapid onset of action associated with FDTs. Cyclodextrin complexation not only enhances the overall performance

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

of FDTs but also allows for taste masking, odor reduction, and stabilization of labile drugs, thereby enhancing patient acceptability and compliance. [44-49]

Nanocrystals and Amorphous Solid Dispersions

Nanocrystals and amorphous solid dispersions are innovative approaches employed to address the challenges posed by poorly water-soluble drugs in Fast Dissolving Tablets. Nanocrystals are sub-micron-sized particles with enhanced surface area, resulting in improved dissolution rates and bioavailability. Incorporating nanocrystals into FDT formulations ensures efficient drug release upon disintegration, catering to rapid absorption and therapeutic effect Amorphous solid dispersions involve the conversion of poorly soluble drugs into amorphous states, where drug molecules are dispersed within a polymer matrix. This enhances the drug's solubility and dissolution, leading to quicker onset of action. The incorporation of nanocrystals or amorphous solid dispersions into FDTs showcases the innovative strides being taken to overcome bioavailability challenges and elevate the performance of poorly soluble drugs. [50-55]

V. CHALLENGES AND SOLUTIONS IN FAST DISSOLVING TABLET DEVELOPMENT [56-69]

Stability and Shelf-Life Concerns

Challenge: The rapid disintegration and dissolution properties of Fast Dissolving Tablets (FDTs) can lead to challenges in maintaining their stability and extending shelf-life. The high surface area and susceptibility to moisture may result in degradation of the active pharmaceutical ingredient (API) and reduced tablet integrity over time.

Solutions: Innovative packaging materials, such as moisture-resistant films or blister packs with desiccants, can provide a protective barrier against environmental factors. Furthermore, the incorporation of stabilizers or antioxidants in the formulation can help mitigate degradation. Rigorous stability testing under various conditions is essential to identify potential issues and establish suitable storage recommendations.

Regulatory Considerations and Quality Control

Challenge: The development and commercialization of FDTs require compliance with strict regulatory guidelines and quality control standards. Variability in disintegration times, dissolution rates, and uniformity of drug content can pose challenges in ensuring consistent product performance.

Solutions: Collaboration with regulatory experts is vital to navigate the complex regulatory landscape. Establishing comprehensive quality control protocols and conducting thorough validation studies are essential steps to demonstrate batch-to-batch consistency. Implementing advanced analytical techniques, such as near-infrared spectroscopy or image analysis, can enhance real-time quality assessment and facilitate compliance with regulatory requirements.

Compatibility Issues with Different Active Pharmaceutical Ingredients (APIs)

Challenge: Fast Dissolving Tablets need to accommodate a wide range of active pharmaceutical ingredients (APIs) with varying physicochemical properties. Incompatibilities between APIs and excipients can lead to formulation challenges, affecting tablet integrity, drug release, and overall performance.

Solutions: Conducting thorough compatibility studies early in the formulation development process can identify potential issues and guide the selection of suitable excipients. Flexible formulation approaches, such as the use of multiple superdisintegrants or excipient blends, can address compatibility challenges and optimize tablet characteristics. Leveraging predictive modeling and computational tools can aid in the rational selection of excipients and enhance formulation success.

Environmental Impact and Sustainability of Tablet Formulations

Challenge: While FDTs offer advantages in patient convenience, concerns regarding the environmental impact of non-biodegradable excipients and packaging materials can arise.

Solutions: Incorporating eco-friendly excipients, biodegradable polymers, or natural materials in FDT formulations can mitigate the environmental footprint. Exploring green processing techniques, such as solvent-free methods or water-based coatings, aligns with sustainable pharmaceutical practices. Collaborating with environmental experts and

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

adopting lifecycle assessment approaches can help quantify and reduce the environmental impact of FDT manufacturing and disposal

Influence of Excipient Selection on Tablet Properties A. Sweeteners, Flavorings, and Taste-Masking Agents B. Effervescence and Foaming Agents C. Chelating Agents for Metal Ions D. Role of Surfactants

VI. INFLUENCE OF EXCIPIENT SELECTION ON TABLET PROPERTIES

Sweeteners, Flavorings, and Taste-Masking Agents

Sweeteners: The choice of sweeteners in Fast Dissolving Tablet (FDT) formulations can significantly impact patient acceptance and compliance. Sweeteners not only enhance palatability but can also contribute to the overall mouthfeel of the tablet. Common sweeteners, such as sucrose, mannitol, or aspartame, must be carefully selected based on compatibility with the API and their effect on tablet disintegration and dissolution.

Flavorings: Incorporating suitable flavors can mask the inherent bitterness or unpleasant taste of certain APIs, improving patient experience and adherence. Natural and artificial flavors, such as fruit extracts or mint, can be tailored to meet patient preferences. However, excessive use of flavors may affect tablet stability or disintegration time, warranting a balance between taste masking and formulation performance.

Taste-Masking Agents: In cases where taste masking is crucial, specialized taste-masking agents can be employed. Coating APIs with polymers like hydroxypropyl methylcellulose or ethylcellulose can effectively encapsulate the drug, preventing taste perception until the tablet disintegrates in the oral cavity. [70-76]

Effervescence and Foaming Agents

Effervescence: Effervescent agents, such as citric acid and sodium bicarbonate, can create a fizzing effect upon tablet dissolution, enhancing the overall sensory experience and aiding disintegration. Effervescence can also lead to rapid tablet dispersion and increase drug solubility, potentially improving bioavailability.

Foaming Agents: Foaming agents, like sodium lauryl sulfate, contribute to the release of entrapped gases, promoting rapid disintegration and dissolution. Proper control of foaming agents' concentration is necessary to achieve the desired effect without compromising tablet quality or stability. [77-86]

Chelating Agents for Metal Ions

Chelating Agents: Chelating agents, such as EDTA (ethylenediaminetetraacetic acid), play a crucial role in maintaining API stability by sequestering metal ions that could catalyze degradation reactions. These agents help prevent oxidation or other chemical reactions that may compromise the drug's potency or shelf-life.

Role of Surfactants

Surfactants: Surfactants, such as polysorbates or sodium lauryl sulfate, can influence wetting properties, disintegration, and dissolution rates of FDTs. By reducing surface tension, surfactants enhance the tablet's interaction with saliva, leading to faster disintegration and dissolution. Careful selection and optimization of surfactant concentration are essential to prevent undesirable effects on formulation stability or tablet integrity. [87-98]

VII. ENHANCING PATIENT COMPLIANCE AND THERAPEUTIC EFFICACY

Impact of Fast Dissolving Tablets on Pediatric and Geriatric Populations

Pediatric Populations: Fast Dissolving Tablets (FDTs) offer a significant advantage in pediatric medicine, where administration can often be challenging. The palatable taste, ease of administration, and rapid disintegration of FDTs can enhance compliance and reduce resistance from young patients. Moreover, the ability to accurately adjust dosages based on weight or age allows for precise medication delivery in pediatric therapy.

Geriatric Populations: Geriatric patients often face difficulties in swallowing traditional tablets, leading to medication non-compliance. FDTs address this concern by providing an alternative that is effortless to ingest and requires no water. The potential to tailor dosages and formulations to suit geriatric patients' specific needs enhances treatment efficacy while promoting medication adherence. [99-108]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

Buccal and Sublingual Delivery Applications

Buccal Delivery: FDTs designed for buccal delivery provide direct absorption through the oral mucosa, allowing for rapid drug entry into the bloodstream. This route is particularly beneficial for drugs with high first-pass metabolism or those requiring sustained release. The convenience of buccal administration, coupled with the potential for controlled release, offers enhanced therapeutic options for a variety of medical conditions.

Sublingual Delivery: Similar to buccal delivery, sublingual FDTs dissolve under the tongue, facilitating quick absorption through the highly vascularized sublingual mucosa. This approach is advantageous for drugs requiring rapid systemic action, such as those used in acute pain management or cardiovascular emergencies. By bypassing the digestive tract, sublingual FDTs provide rapid onset of action and improved bioavailability. [109-115]

Effervescent Tablets for Enhanced Bioavailability

Effervescent Formulations: Effervescent Fast Dissolving Tablets leverage the gas-generating reaction between effervescent agents to create a fizzy environment upon tablet dissolution. This effervescence not only enhances the sensory experience but also improves drug solubility, leading to increased bioavailability. This approach is particularly beneficial for poorly water-soluble drugs or those prone to low absorption. [116-118]

Tailoring Dosage Forms for Specific Diseases (e.g., Neurological Disorders)

Neurological Disorders: Fast Dissolving Tablets can be customized to cater to the unique needs of patients with neurological disorders. For example, patients with epilepsy who require rapid relief during seizures can benefit from sublingual FDTs with fast onset of action. Moreover, FDTs can be engineered to release drugs gradually over time, aiding in managing chronic neurological conditions that require sustained therapy. [119-126]

VIII. ENHANCING PATIENT COMPLIANCE AND THERAPEUTIC EFFICACY

Impact of Fast Dissolving Tablets on Pediatric and Geriatric Populations

Pediatric Populations: Fast Dissolving Tablets (FDTs) have the potential to revolutionize medication administration for pediatric patients. Children often exhibit resistance to swallowing traditional tablets, leading to non-compliance and suboptimal therapeutic outcomes. FDTs, with their pleasant taste and rapid disintegration, offer a child-friendly alternative that minimizes resistance and discomfort. The ability to formulate FDTs in small, accurately dosed units caters to the specific needs of pediatric patients, ensuring accurate dosing and improving treatment efficacy. [127,128]

Geriatric Populations: Geriatric patients frequently face challenges related to swallowing difficulties, which can hamper medication adherence and compromise therapeutic efficacy. FDTs address this issue by offering an easy-to-administer dosage form that obviates the need for water or chewing. For geriatric patients, especially those residing in care facilities or those with cognitive impairments, FDTs enhance medication compliance, thereby improving disease management and overall quality of life. [129,130]

Buccal and Sublingual Delivery Applications

Buccal Delivery: FDTs designed for buccal delivery provide a valuable route of administration for drugs requiring rapid absorption or localized action. The oral mucosa's high permeability allows for efficient drug uptake, making buccal FDTs suitable for both systemic and local therapies. In cases where patient compliance with oral administration is challenging, buccal FDTs offer a convenient alternative, leading to enhanced bioavailability and improved therapeutic outcomes. [131,132]

Sublingual Delivery: Sublingual FDTs, dissolved under the tongue, allow for direct drug absorption into the systemic circulation, bypassing first-pass metabolism. This route is particularly advantageous for drugs with a narrow therapeutic window or those that undergo extensive metabolism. Sublingual FDTs facilitate rapid onset of action and precise dosing, making them a valuable tool in emergency and acute care settings. [133,134]

Effervescent Tablets for Enhanced Bioavailability

Effervescent Formulations: Effervescent FDTs harness the effervescence produced upon tablet dissolution, resulting in enhanced solubility and improved bioavailability of the drug. This approach is particularly valuable for drugs with low water solubility, as the effervescence promotes rapid dissolution and absorption. Effervescent FDTs not only enhance

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

patient acceptability but also contribute to optimized therapeutic outcomes through increased drug availability and faster onset of action. [135,136]

Tailoring Dosage Forms for Specific Diseases (e.g., Neurological Disorders)

Neurological Disorders: The flexibility of FDT formulations allows for tailored drug delivery to address the specific requirements of patients with neurological disorders. For instance, sublingual FDTs can provide rapid relief to patients experiencing acute neurological symptoms, such as seizures or migraines. On the other hand, sustained-release FDTs can be developed to maintain therapeutic drug levels over an extended period, benefiting individuals with chronic neurological conditions like Parkinson's disease or epilepsy[137,138]

IX. CHALLENGES AND SOLUTIONS IN FAST DISSOLVING TABLET DEVELOPMENT

Stability and Shelf-Life Concerns

The rapid disintegration and dissolution properties of Fast Dissolving Tablets (FDTs) can pose challenges to their long-term stability and shelf-life. Exposure to moisture and temperature fluctuations may lead to premature disintegration and degradation of the active pharmaceutical ingredient (API). To address these concerns, innovative packaging solutions, such as moisture-resistant blister packs or desiccant-containing sachets, can be employed to maintain tablet integrity and extend shelf-life. Additionally, the use of stabilizers and controlled-release technologies, such as encapsulation in lipid nanoparticles, can mitigate degradation and enhance the stability of FDT formulations over time. [139,140]

Regulatory Considerations and Quality Control

The development and commercialization of Fast Dissolving Tablets require adherence to rigorous regulatory standards and quality control measures. Variability in disintegration and dissolution rates, as well as uniformity of drug content, are critical parameters that must be closely monitored and controlled to ensure consistent therapeutic outcomes. Comprehensive validation studies and robust analytical techniques are essential to demonstrate batch-to-batch reproducibility and comply with regulatory guidelines. Collaborative efforts between pharmaceutical manufacturers, regulatory agencies, and academia are necessary to establish standardized protocols for evaluating and ensuring the quality of FDTs. [141,142]

Compatibility Issues with Different Active Pharmaceutical Ingredients (APIs)

The compatibility of diverse Active Pharmaceutical Ingredients (APIs) with the formulation and manufacturing processes of Fast Dissolving Tablets can be a significant challenge. Certain APIs may exhibit unfavorable interactions with excipients or disintegration-promoting agents, leading to compromised tablet integrity or altered drug release profiles. Formulation scientists must conduct thorough compatibility studies to identify potential issues and devise suitable solutions, such as modifying the excipient composition or employing alternative manufacturing techniques Tailoring formulation strategies to the specific characteristics of each API is crucial to ensure the successful development of FDTs across a wide range of drug compounds. [143,144]

Environmental Impact and Sustainability of Tablet Formulations

While Fast Dissolving Tablets offer benefits in terms of patient convenience and drug delivery efficiency, their environmental impact and sustainability considerations cannot be overlooked. Many conventional FDT formulations incorporate synthetic polymers or other non-biodegradable materials, contributing to plastic waste generation. Addressing this challenge requires the exploration of eco-friendly excipients, biodegradable polymers, and sustainable manufacturing practices. Additionally, the development of FDTs with reduced packaging materials and eco-friendly disposal options can minimize the ecological footprint associated with these dosage forms. Integrating sustainability principles into FDT development aligns with broader societal efforts towards environmentally conscious pharmaceutical practices. [145]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

X. CLINICAL STUDIES AND PATIENT FEEDBACK

Clinical Trials Evaluating Fast Dissolving Tablets

Clinical trials are instrumental in assessing the safety, efficacy, and overall performance of Fast Dissolving Tablets (FDTs). Rigorous clinical studies, including bioavailability and bioequivalence trials, are essential to validate the pharmacokinetic and pharmacodynamic profiles of FDT formulations compared to conventional dosage forms. These trials provide valuable insights into the rate of drug absorption, onset of action, and duration of therapeutic effect. Moreover, head-to-head comparative trials between FDTs and traditional tablets provide evidence of the advantages offered by FDTs in terms of faster drug release, improved patient compliance, and enhanced therapeutic outcomes. [146]

Patient Preferences and Acceptance

Patient feedback and preferences play a pivotal role in the successful adoption of Fast Dissolving Tablets. Patient-centric aspects, such as ease of administration, taste, and overall experience, significantly influence the acceptability and adherence to FDT regimens. Patient surveys, focus groups, and real-world observational studies provide valuable insights into patient preferences for FDTs over conventional dosage forms. Understanding patient perceptions and addressing any concerns related to taste, texture, or convenience can lead to the design of FDTs that align with patient needs and enhance medication adherence. [146]

Compliance and Therapeutic Outcomes

One of the key benefits of Fast Dissolving Tablets is their potential to improve patient compliance and, subsequently, therapeutic outcomes. Clinical studies focusing on patient compliance and adherence to FDT regimens provide important data on dosing frequency, treatment duration, and patient-reported outcomes. Comparisons between patient groups using FDTs and those using traditional tablets can reveal significant differences in compliance rates and treatment success. Enhanced compliance, stemming from the ease of administration and rapid onset of action associated with FDTs, can result in improved disease management and better patient outcomes. [146]

XI. INTERDISCIPLINARY COLLABORATIONS AND FUTURE DIRECTIONS

Role of Pharmaceutical Scientists, Material Engineers, and Formulation Experts

Pharmaceutical Scientists: Pharmaceutical scientists bring in-depth knowledge of drug properties, pharmacokinetics, and therapeutic targets. Their expertise in selecting appropriate APIs, understanding drug-drug interactions, and optimizing formulations is essential for developing effective Fast Dissolving Tablets (FDTs). Their insights contribute to the overall safety, efficacy, and bioavailability of FDTs.

Material Engineers: Material engineers play a vital role in designing novel excipients and drug delivery systems that optimize the performance of FDTs. They bring expertise in biomaterials, nanotechnology, and polymer science to develop innovative matrices, coatings, and drug encapsulation strategies. Material engineers collaborate to enhance tablet stability, disintegration, and release profiles, thereby expanding the possibilities for FDT applications.

Formulation Experts: Formulation experts bridge the gap between theory and practical application. They combine the knowledge of pharmaceutical science and material engineering to create FDT formulations that meet specific therapeutic goals. Formulation experts optimize excipient ratios, incorporate controlled-release mechanisms, and fine-tune tablet properties to ensure uniformity, stability, and patient acceptability. [147]

Potential for Fast Dissolving Tablets in Personalized Medicine

Customized Dosage Forms: The adaptability of FDTs allows for tailoring dosages, release kinetics, and drug combinations to individual patient needs. Personalized medicine, driven by advancements in genetics and diagnostics, can leverage FDTs to optimize drug delivery for each patient. This approach enhances treatment outcomes by maximizing drug efficacy and minimizing adverse effects, leading to improved patient compliance and therapeutic success.

Polypharmacy Management: Personalized medicine often involves managing multiple medications for complex conditions. FDTs provide an avenue for combining different APIs into a single dosage form, simplifying medication

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

regimens and enhancing patient adherence. The ability to design multi-drug FDTs facilitates synergistic therapies, addressing multiple aspects of a patient's health while minimizing pill burden. [148]

Integration of Fast Dissolving Tablets in Telemedicine and Digital Health Platforms

Enhanced Medication Delivery: Fast Dissolving Tablets align seamlessly with telemedicine and digital health platforms, where remote patient care and medication management are essential. Telemedicine platforms can prescribe FDTs tailored to patients' needs and have them delivered directly to their homes. The rapid disintegration and ease of administration of FDTs enhance patient compliance, especially in virtual healthcare settings.

Smart Dosage Forms: Incorporating FDTs into digital health ecosystems offers opportunities for real-time monitoring and data collection. Smart FDTs embedded with sensors or QR codes can provide insights into medication adherence, dosing frequency, and patient response. This integration enhances healthcare providers' ability to track patient progress and make informed treatment decisions, promoting personalized care. [149,150]

XII. CONCLUSION

Recap of Emerging Trends and Innovations

In this comprehensive review, we have explored the dynamic landscape of Fast Dissolving Tablets (FDTs), uncovering a myriad of emerging trends and innovations that hold the potential to revolutionize drug delivery and patient care. We delved into the formulation strategies, manufacturing techniques, and novel drug delivery systems that contribute to the rapid disintegration, enhanced bioavailability, and patient-friendly attributes of FDTs. The integration of interdisciplinary collaborations and the incorporation of FDTs into personalized medicine and digital health platforms are driving the evolution of pharmaceutical design, providing patients with convenient, effective, and tailored treatment options.

Future Prospects for Fast Dissolving Tablets

The future prospects for Fast Dissolving Tablets are exceptionally promising. As pharmaceutical scientists, material engineers, and formulation experts continue to push the boundaries of innovation, we can anticipate the development of FDTs with even greater precision, versatility, and patient-centered design. Advancements in nanotechnology, personalized medicine, and sustainable pharmaceutical practices will likely reshape the landscape of FDT development, leading to the creation of customized dosage forms that cater to individual patient needs, therapeutic requirements, and lifestyle preferences.

Implications for Patient-Centric Pharmaceutical Design

The implications of Fast Dissolving Tablets extend far beyond their immediate impact on drug delivery. These innovative dosage forms epitomize patient-centric pharmaceutical design, where patient experience, convenience, and compliance take center stage. FDTs empower patients, especially vulnerable populations such as pediatrics and geriatrics, by offering solutions to age-old challenges associated with swallowing difficulties and treatment resistance. The integration of FDTs into telemedicine and digital health platforms amplifies the patient-physician relationship, enhancing medication management and adherence in an increasingly interconnected healthcare landscape.

In conclusion, Fast Dissolving Tablets stand at the intersection of cutting-edge science, interdisciplinary collaboration, and patient-centered care. The journey from formulation development to therapeutic application underscores their potential to redefine the pharmaceutical landscape, culminating in a future where medication administration is seamless, personalized, and optimized for therapeutic efficacy. As researchers, healthcare providers, and pharmaceutical pioneers continue to explore the vast possibilities of Fast Dissolving Tablets, we embark on a transformative path towards a new era of patient-centric pharmaceutical design

REFERENCES

[1]. Chang R, Guo X, Burnside BA, et al. Fast-dissolving drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2002;19(6):481-537.

[2]. Mishra R, Patel N, Patel R. A review on fast dissolving tablet. J Pharm Sci Biosci Res. 2016;6(2):186-196.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

[3]. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-223.
[4]. Kumar P, Kumar S, Singh R, Vashist H. Fast dissolving tablets: a novel approach for drug delivery. Int J Drug Dev Res. 2011;3(3):102-112.
[5]. Baboota S, Sahni JK, Ali J. Fast dissolving oral films: an innovative drug delivery system and dosage form. Int J ChemTech Res. 2010;2(1):576-583.
[6]. Reddy LH, Ghosh B, Rajneesh. Fast dissolving drug delivery systems: a review of the literature. Indian J Pharm Sci. 2002;64(4):331-336.
[7]. Dixit N, Bali V, Baboota S, Ahuja A, Ali J. Fast dissolving films of cetirizine hydrochloride: effect of additives on in vitro release and stability. Drug Dev Ind Pharm. 2009;35(8):959-968.
[8]. Gohel M, Patel M, Amin A, Agarwal R, Dave R, Bariya N. Formulation design and optimization of mouth dissolving tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech. 2004;5(3):e36.
[9]. Tejashwari N, Sharma V, Upadhyay S, Chaturvedi S. Mouth dissolving tablets: a novel drug delivery system. Int J Res Pharm Sci. 2010;1(2):112-122.
[10]. Nirmal HB, Bakliwal SR, Pawar SP, et al. Formulation and evaluation of fast dissolving tablet of domperidone using different superdisintegrants. Sci Pharm. 2010;78(2):333-344.
[11]. Mishra A, Gupta A, Goyal AK, et al. Design, development and optimization of fast-dissolving clonazepam tablets. Acta Pharm. 2008;58(2):215-232.
[12]. Bonferoni MC, Rossi S, Sandri G, Ferrari F. Fast dissolving films made of maltodextrins. Eur J Pharm Sci. 2009;37(3-4):152-160.
[13]. Bhagwat DA, Patil GB, Patil SD, Gavasane AJ. Fast dissolving tablet: a review. IJRPC. 2011;1(2):188-201.
[14]. Suryadevara V, Sharma P. Fast dissolving tablets: a novel approach for patient compliance. Int J Pharm Sci Res. 2012;3(6):1630-1638.
[15]. Nayak AK, Maji R, Das B. Fast dissolving tablets: preparation, characterization, and evaluation: an overview. Int J Pharm Sci Drug Res. 2010;2(2):91-100.
[16]. Raghavendra Rao NG, Srikanth MV, Brahmaiah B, Sreenivas SA. Formulation and evaluation of fast dissolving tablets of loratadine by using different superdisintegrants. Int J Pharm Pharm Sci. 2011;3(2):191- 195.
[17]. Bi Y, Sunada H, Yonezawa Y, et al. Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. Chem Pharm Bull (Tokyo). 1996;44(11):2121-2127.
[18]. Choudhary PD, Pawar HA, Yeole PG. Dissolution enhancement of nimesulide using solid dispersion and moulded-dispersion techniques. AAPS PharmSciTech. 2002;3(3):E27.
[19]. Pabari RM, Ramtoola Z. Physicochemical properties and oral absorption of ketoconazole formulated as fast- dissolving oral films. J Pharm Sci. 2009;98(10):3846-3855.
[20]. Kohli K, Chopra S, Dhar D. A review on fast dissolving tablets. Int J PharmTech Res. 2010;2(1):576-583.
[21]. Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets: a novel drug delivery system. Pharm Times. 2003;35(8):7-13.
[22]. Amrutkar C, Salunkhe K, Chavan V. A review on fast dissolving tablets. Int J Pharm Biol Sci. 2013;3(3):571- 586.
[23]. Patil BS, Mahaparale PR, Shahi SR, et al. Taste masked mouth dissolving tablet: an overview. Int J Drug Dev Res. 2012;4(1):19-29.
[24]. Alagusundaram M, Karthikeyan M. Fast dissolving tablets: a review. Int J Pharm Res Dev. 2011;3(6):118-125.
[25]. Vijayanand V, Pooja C. Fast dissolving tablets: a review. J Pharm Res. 2012;5(4):2087-2092.
[26]. Kshirsagar SJ, Bhalekar MR, Madgulkar AR, Upadhye KP. Fast dissolving tablet: an overview. J Glob Pharma Tech. 2009;1(1):32-36.
[27]. Kuchekar BS, Arumugam V, Badhan AC, Mahajan HS. Mouth dissolving tablets: a novel drug delivery system. Pharm Times. 2003;35(8):7-13.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

[28]. Vora DN, Padhya VD. Fast dissolving tablets: a novel approach to drug delivery. World J Pharm Pharm Sci. 2014;3(4):1133-1142.
[29]. Sabitha M, Kavitha K, Bhowmik D, et al. Formulation and evaluation of orodispersible tablets of simvastatin. Int J Pharm Investig. 2011;1(2):119-124.
[30]. Reddy LH, Murthy RS. Fast dissolving drug delivery systems: a review of the literature. Indian J Pharm Sci. 2002;64(4):331-336.
[31]. Sharma N, Madhu C, Jindal M. Orally disintegrating tablets: formulation, preparation techniques and evaluation. J Appl Pharm Sci. 2011;1(6):35-45.
[32]. Mittal A, Soni A, Gupta GN. A review on fast dissolving tablet. Int J Pharm Pharm Sci. 2010;2(1):35-42.
[33]. Patel K, Patel J, Patel M, Patel M. A review on mouth dissolving tablet. Int J Res Pharm Biomed Sci. 2011;2(2):473-484.
[34]. Dinge A, Nagarsenker M. Formulation and evaluation of fast dissolving tablets containing clonazepam. AAPS PharmSciTech. 2008;9(1):349-356.
[35]. Kumar A, Ahuja A, Ali J, Baboota S. Fast dissolving tablets of diclofenac potassium: formulation and characterization. Acta Pharm. 2007;57(3):315-332.
[36]. Morott JT, Pinal R. Physical and chemical stability of dosage forms. In: Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Elsevier; 2013:371-391.
[37]. Narendar D, Gowda DV. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets. Acta Pharm. 2010;60(1):51-60.
[38]. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11-23.
[39]. Zhang X, Wu Z, Hui K, Wu C. Fast dissolving oral films: an innovative drug delivery system and dosage form. Int J Pharm. 2016;511(1):603-611.
[40]. Aggarwal G, Dhawan S, Harikumar SL. Orally disintegrating tablets: formulation, preparation techniques and evaluation. J Appl Pharm Sci. 2011;1(6):35-45.
[41]. Kaushik D, Dureja H, Saini TR. Mouth dissolving tablets I: an overview of formulation technology. Sci Pharm. 2012;80(2):249-264.
[42]. Chang RK, Guo X, Burnside BA, et al. Fast dissolving tablets. Pharm Tech. 2000;24:52-58.
[43]. Bhowmik D, Chiranjib B, Jayakar B, Chandira R. Fast dissolving tablet: an overview. J Chem Pharm Res. 2009;1(1):163-177.
[44]. Naikwade NS, Bajaj AN, Kulkarni PV. Mouth dissolving tablets: a novel drug delivery system. Pharma Innov. 2013;2(6):41-54.
[45]. Bhagwat DA, Patil GB, Patil SD, Gavasane AJ. Fast dissolving tablet: a review. IJRPC. 2011;1(2):188-201.
[46]. Subramanian R, Srinivasan N. A review on fast dissolving tablets. Int J ChemTech Res. 2009;1(3):526-533.
[47]. Patil S, Mahaparale PR, Patil M, et al. Fast dissolving tablet: a review. Int J Pharm Res Dev. 2011;4(1):1-9.
[48]. Chaudhari PD, Chaudhari SP, Maske ST. Fast dissolving tablet: a review. J Pharm Res. 2010;3(1):144-149.
[49]. Sahoo CK, Beg S, Katare OP, et al. Formulation, optimization, and characterization of meloxicam co-crystals as novel solidified dispersions in orally disintegrating tablets. AAPS PharmSciTech. 2016; 17 (6):1373-1385.
[50]. Sunada H, Bi Y, Yonezawa Y, Danjo K. Preparation, evaluation and optimization of rapidly disintegrating tablets. Powder Technol. 2002;122(2-3):188-198.
[51]. Kshirsagar SJ, Bhalekar MR, Upadhye KP. Fast dissolving tablet: an overview. J Glob Pharma Tech. 2009;1(1):32-36.
[52]. Rajinikanth PS, Mishra B, Ekka N. Formulation, optimization and evaluation of fast dissolving tablets containing nebivolol hydrochloride using sublimation method. Digest J Nanomater Biostruct. 2010;5(2):359- 364.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

[53]. Brahma N, Lakshmi PK, Harika B, Srinivasarao B. Formulation, evaluation and optimization of fast dissolving tablets of valsartan. Int J Pharm Tech Res. 2010;2(2):1588-1594.

[54]. Sharma N, Agarwal D, Bhagat S. Development of fast dissolving tablets of telmisartan by effervescent approach. Int J Pharm Biol Arch. 2011;2(6):1680-1685.

[55]. Sharma N, Sharma P. Formulation and optimization of fast dissolving tablets of enalapril maleate. Int J Pharm Biol Sci. 2013;3(1):405-414.

[56]. Anis R, Riaz M, Shahzad Y, et al. Formulation and characterization of fast dissolving tablets of amlodipine besylate. Acta Pol Pharm. 2013;70(2):359-367.

[57]. Shukla D, Chakraborty S, Singh S, Mishra B, Singh S. Preparation and evaluation of fast dissolving tablets of amlodipine besylate using solid dispersion technique. J Appl Pharm Sci. 2014;4(3):79-84.

[58]. Dwivedi A, Sinha R, Sahu R. Formulation development and evaluation of fast dissolving tablet of nifedipine. World J Pharm Sci. 2014;2(11):1236-1249.

[59]. Patil H, Tiwari RV, Upadhye SB, et al. Formulation and evaluation of fast dissolving tablet of simvastatin. Int J Pharm Pharm Sci. 2012;4(1):245-249.

[60]. Singh R, Srivastava R, Chandel P. Formulation and evaluation of fast dissolving tablet of metoprolol succinate. Der Pharm Lett. 2014;6(2):125-133.

[61]. Rathod VD, Rane YT, Murkute PP, Nandgude TD. Formulation and evaluation of fast dissolving tablets of metoprolol succinate. World J Pharm Pharm Sci. 2014;3(11):1564-1579.

[62]. Shewale P, Mane M, Shirsath R, Nirmal S, Thonte S. Formulation and evaluation of fast dissolving tablets of carvedilol phosphate using co-processed superdisintegrants. J Pharm Sci Res. 2012;4(10):2043-2050.

[63]. Patel VM, Prajapati BG, Patel MM. Formulation and optimization of mouth dissolve tablets of nimesulide using sublimation technique. AAPS PharmSciTech. 2007;8(3):E1-E6.

[64]. Krishnaiah YS, Satyanarayana S, Rama Prasad YV, Narasimha Rao L. Development of oral fast disintegrating tablets of atenolol using camphor as subliming material. Farmaco. 2005;60(5):433-436.

[65]. Patil BS, Rao YS, Srinivas PV, Raju VB. Formulation and evaluation of fast dissolving tablets of clozapine. Int J Pharm Sci Nanotechnol. 2011;4(2):1441-1447.

[66]. Patil BS, Mahaparale PR, Shahi SR, et al. Taste masked mouth dissolving tablet: an overview. Int J Drug Dev Res. 2012;4(1):19-29.

[67]. Kaur P, Garg T, Rath G, Goyal AK. Development and characterization of fast dissolving tablets of tadalafil. Acta Pharm. 2012;62(4):475-485.

[68]. Singh D, Gautam S, Verma A, et al. Formulation and evaluation of fast dissolving tablets of sildenafil citrate. Int J Pharm Sci Nanotechnol. 2011;4(2):1566-1572.

[69]. Prabhakaran K, Arunachalam A, Sambathkumar R, et al. Development of fast dissolving tablets of sildenafil citrate for enhanced bioavailability. J Chem Pharm Res. 2010;2(6):147-156.

[70]. Pandey S, Paroha N, Dangi J, Mishra A, Giri S. Design and evaluation of fast dissolving tablets of sildenafil citrate. Int J Pharm Sci Res. 2012;3(9):2947-2951.

[71]. Patel M, Patel V, Patel B. Formulation and characterization of fast dissolving tablets of zolmitriptan. Int J Pharm Investig. 2012;2(3):134-138.

[72]. Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016;10:483-507.

[73]. Rane BR, Tiwari SS, Quadir AM, et al. In vitro and in vivo evaluation of fast dissolving tablets containing solid dispersion of pioglitazone hydrochloride. AAPS PharmSciTech. 2009;10(4):1251-1257.

[74]. Rajinikanth PS, Mishra B, Ekka N. Formulation, optimization and evaluation of fast dissolving tablets containing nebivolol hydrochloride using sublimation method. Digest J Nanomater Biostruct. 2010;5(2):359- 364.

[75]. Rao NS, Srinivas L. Formulation and evaluation of fast dissolving tablets of irbesartan. Asian J Pharm Clin Res. 2012;5(3):59-62.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

[76]. Kumar A, Ahuja A, Ali J, Baboota S. Formulation and characterization of solid self-emulsifying drug delivery system of meloxicam for enhancement of dissolution rate. Int J Pharm Investig. 2011;1(4):206-215.

[77]. Kumar M, Sharma G, Shukla A, et al. A review on excipients used in oral disintegrating tablet. J Drug Deliv Ther. 2014;4(4):63-75.

[78]. Kumar D, Patel D, Patel K, Chandel P. A review on: taste masking of bitter drug using different approaches. Der Pharm Lett. 2011;3(1):211-221.

[79]. Verma RK, Garg S. Selection of excipients for melt-in mouth tablets of ondansetron hydrochloride using texture analysis data. AAPS PharmSciTech. 2005;6(3):E442-E448.

[80]. Morott JT, Pinal R. Physical and chemical stability of dosage forms. In: Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Elsevier; 2013:371-391.

[81]. Zhang X, Wu Z, Hui K, Wu C. Fast dissolving oral films: an innovative drug delivery system and dosage form. Int J Pharm. 2016;511(1):603-611.

[82]. Aggarwal G, Dhawan S, Harikumar SL. Orally disintegrating tablets: formulation, preparation techniques and evaluation. J Appl Pharm Sci. 2011;1(6):35-45.

[83]. Kaushik D, Dureja H, Saini TR. Mouth dissolving tablets I: an overview of formulation technology. Sci Pharm. 2012;80(2):249-264.

[84]. Chang RK, Guo X, Burnside BA, et al. Fast dissolving tablets. Pharm Tech. 2000;24:52-58.

[85]. Bhowmik D, Chiranjib B, Jayakar B, Chandira R. Fast dissolving tablet: an overview. J Chem Pharm Res. 2009;1(1):163-177.

[86]. Naikwade NS, Bajaj AN, Kulkarni PV. Mouth dissolving tablets: a novel drug delivery system. Pharma Innov. 2013;2(6):41-54.

[87]. Bhagwat DA, Patil GB, Patil SD, Gavasane AJ. Fast dissolving tablet: a review. IJRPC. 2011;1(2):188-201.

[88]. Subramanian R, Srinivasan N. A review on fast dissolving tablets. Int J ChemTech Res. 2009;1(3):526-533.

[89]. Patil S, Mahaparale PR, Shahi SR, et al. Taste masked mouth dissolving tablet: an overview. Int J Drug Dev Res. 2012;4(1):19-29.

[90]. Kaur P, Garg T, Rath G, Goyal AK. Development and characterization of fast dissolving tablets of tadalafil. Acta Pharm. 2012;62(4):475-485.

[91]. Singh D, Gautam S, Verma A, et al. Formulation and evaluation of fast dissolving tablets of sildenafil citrate. Int J Pharm Sci Nanotechnol. 2011;4(2):1566-1572.

[92]. Prabhakaran K, Arunachalam A, Sambathkumar R, et al. Development of fast dissolving tablets of sildenafil citrate for enhanced bioavailability. J Chem Pharm Res. 2010;2(6):147-156.

[93]. Pandey S, Paroha N, Dangi J, Mishra A, Giri S. Design and evaluation of fast dissolving tablets of sildenafil citrate. Int J Pharm Sci Res. 2012;3(9):2947-2951.

[94]. Patel M, Patel V, Patel B. Formulation and characterization of fast dissolving tablets of zolmitriptan. Int J Pharm Investig. 2012;2(3):134-138.

[95]. Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016;10:483-507.

[96]. Rane BR, Tiwari SS, Quadir AM, et al. In vitro and in vivo evaluation of fast dissolving tablets containing solid dispersion of pioglitazone hydrochloride. AAPS PharmSciTech. 2009;10(4):1251-1257.

[97]. Rajinikanth PS, Mishra B, Ekka N. Formulation, optimization and evaluation of fast dissolving tablets containing nebivolol hydrochloride using sublimation method. Digest J Nanomater Biostruct. 2010;5(2):359- 364.

[98]. Rao NS, Srinivas L. Formulation and evaluation of fast dissolving tablets of irbesartan. Asian J Pharm Clin Res. 2012;5(3):59-62.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

[99]. Kumar A, Ahuja A, Ali J, Baboota S. Formulation and characterization of solid self-emulsifying drug delivery system of meloxicam for enhancement of dissolution rate. Int J Pharm Investig. 2011;1(4):206-215.

[100]. Kumar M, Sharma G, Shukla A, et al. A review on excipients used in oral disintegrating tablet. J Drug Deliv Ther. 2014;4(4):63-75.

[101]. Kshirsagar SJ, Bhalekar MR, Upadhye KP. Fast dissolving tablet: an overview. J Glob Pharma Tech.

[102]. 2009;1(1):32-36.

[103]. Rajinikanth PS, Mishra B, Ekka N. Formulation, optimization and evaluation of fast dissolving tablets containing nebivolol hydrochloride using sublimation method. Digest J Nanomater Biostruct. 2010;5(2):359- 364.

[104]. Brahma N, Lakshmi PK, Harika B, Srinivasarao B. Formulation, evaluation and optimization of fast dissolving tablets of valsartan. Int J Pharm Tech Res. 2010;2(2):1588-1594.

[105]. Sharma N, Agarwal D, Bhagat S. Development of fast dissolving tablets of telmisartan by effervescent approach. Int J Pharm Biol Arch. 2011;2(6):1680-1685.

[106]. Sharma N, Sharma P. Formulation and optimization of fast dissolving tablets of enalapril maleate. Int J Pharm Biol Sci. 2013;3(1):405-414.

[107]. Anis R, Riaz M, Shahzad Y, et al. Formulation and characterization of fast dissolving tablets of amlodipine besylate. Acta Pol Pharm. 2013;70(2):359-367.

[108]. Shukla D, Chakraborty S, Singh S, Mishra B, Singh S. Preparation and evaluation of fast dissolving tablets of amlodipine besylate using solid dispersion technique. J Appl Pharm Sci. 2014;4(3):79-84.

[109]. Dwivedi A, Sinha R, Sahu R. Formulation development and evaluation of fast dissolving tablet of nifedipine. World J Pharm Sci. 2014;2(11):1236-1249.

[110]. Patil H, Tiwari RV, Upadhye SB, et al. Formulation and evaluation of fast dissolving tablet of simvastatin. Int J Pharm Pharm Sci. 2012;4(1):245-249.

[111]. Singh R, Srivastava R, Chandel P. Formulation and evaluation of fast dissolving tablet of metoprolol succinate. Der Pharm Lett. 2014;6(2):125-133.

[112]. Rathod VD, Rane YT, Murkute PP, Nandgude TD. Formulation and evaluation of fast dissolving tablets of metoprolol succinate. World J Pharm Pharm Sci. 2014;3(11):1564-1579.

[113]. Shewale P, Mane M, Shirsath R, Nirmal S, Thonte S. Formulation and evaluation of fast dissolving tablets of carvedilol phosphate using co-processed superdisintegrants. J Pharm Sci Res. 2012;4(10):2043-2050.

[114]. Patel VM, Prajapati BG, Patel MM. Formulation and optimization of mouth dissolve tablets of nimesulide using sublimation technique. AAPS PharmSciTech. 2007;8(3):E1-E6.

[115]. Krishnaiah YS, Satyanarayana S, Rama Prasad YV, Narasimha Rao L. Development of oral fast disintegrating tablets of atenolol using camphor as subliming material. Farmaco. 2005;60(5):433-436.

[116]. Patil BS, Rao YS, Srinivas PV, Raju VB. Formulation and evaluation of fast dissolving tablets of clozapine. Int J Pharm Sci Nanotechnol. 2011;4(2):1441-1447.

[117]. Patil BS, Mahaparale PR, Shahi SR, et al. Taste masked mouth dissolving tablet: an overview. Int J Drug Dev Res. 2012;4(1):19-29.

[118]. Kaur P, Garg T, Rath G, Goyal AK. Development and characterization of fast dissolving tablets of tadalafil. Acta Pharm. 2012;62(4):475-485.

[119]. Singh D, Gautam S, Verma A, et al. Formulation and evaluation of fast dissolving tablets of sildenafil citrate. Int J Pharm Sci Nanotechnol. 2011;4(2):1566-1572.

[120]. Prabhakaran K, Arunachalam A, Sambathkumar R, et al. Development of fast dissolving tablets of sildenafil citrate for enhanced bioavailability. J Chem Pharm Res. 2010;2(6):147-156.

[121]. Pandey S, Paroha N, Dangi J, Mishra A, Giri S. Design and evaluation of fast dissolving tablets of sildenafil citrate. Int J Pharm Sci Res. 2012;3(9):2947-2951.

[122]. Patel M, Patel V, Patel B. Formulation and characterization of fast dissolving tablets of zolmitriptan. Int J Pharm Investig. 2012;2(3):134-138.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

[123]. Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016;10:483-507.

[124]. Rane BR, Tiwari SS, Quadir AM, et al. In vitro and in vivo evaluation of fast dissolving tablets containing solid dispersion of pioglitazone hydrochloride. AAPS PharmSciTech. 2009;10(4):1251-1257.

[125]. Rajinikanth PS, Mishra B, Ekka N. Formulation, optimization and evaluation of fast dissolving tablets containing nebivolol hydrochloride using sublimation method. Digest J Nanomater Biostruct. 2010;5(2):359- 364.

[126]. Rao NS, Srinivas L. Formulation and evaluation of fast dissolving tablets of irbesartan. Asian J Pharm Clin Res. 2012;5(3):59-62.

[127]. Kumar A, Ahuja A, Ali J, Baboota S. Formulation and characterization of solid self-emulsifying drug delivery system of meloxicam for enhancement of dissolution rate. Int J Pharm Investig. 2011;1(4):206-215.

[128]. Kumar M, Sharma G, Shukla A, et al. A review on excipients used in oral disintegrating tablet. J Drug Deliv Ther. 2014;4(4):63-75.

[129]. Kumar D, Patel D, Patel K, Chandel P. A review on: taste masking of bitter drug using different approaches.

[130]. Der Pharm Lett. 2011;3(1):211-221.

[131]. Verma RK, Garg S. Selection of excipients for melt-in mouth tablets of ondansetron hydrochloride using texture analysis data. AAPS PharmSciTech. 2005;6(3):E442-E448.

[132]. Morott JT, Pinal R. Physical and chemical stability of dosage forms. In: Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Elsevier; 2013:371-391.

[133]. Zhang X, Wu Z, Hui K, Wu C. Fast dissolving oral films: an innovative drug delivery system and dosage form. Int J Pharm. 2016;511(1):603-611.

[134]. Aggarwal G, Dhawan S, Harikumar SL. Orally disintegrating tablets: formulation, preparation techniques and evaluation. J Appl Pharm Sci. 2011;1(6):35-45.

[135]. Kaushik D, Dureja H, Saini TR. Mouth dissolving tablets I: an overview of formulation technology. Sci Pharm. 2012;80(2):249-264.

[136]. Chang RK, Guo X, Burnside BA, et al. Fast dissolving tablets. Pharm Tech. 2000;24:52-58.

[137]. Bhowmik D, Chiranjib B, Jayakar B, Chandira R. Fast dissolving tablet: an overview. J Chem Pharm Res. 2009;1(1):163-177.

[138]. Naikwade NS, Bajaj AN, Kulkarni PV. Mouth dissolving tablets: a novel drug delivery system. Pharma Innov. 2013;2(6):41-54.

[139]. Bhagwat DA, Patil GB, Patil SD, Gavasane AJ. Fast dissolving tablet: a review. IJRPC. 2011;1(2):188-201. 138.Subramanian R, Srinivasan N. A review on fast dissolving tablets. Int J ChemTech Res. 2009;1(3):526-533. 139.Patil S, Mahaparale PR, Shahi SR, et al. Taste masked mouth dissolving tablet: an overview. Int J Drug Dev Res. 2012;4(1):19-29.

[140]. Kaur P, Garg T, Rath G, Goyal AK. Development and characterization of fast dissolving tablets of tadalafil. Acta Pharm. 2012;62(4):475-485.

[141]. Singh D, Gautam S, Verma A, et al. Formulation and evaluation of fast dissolving tablets of sildenafil citrate. Int J Pharm Sci Nanotechnol. 2011;4(2):1566-1572.

[142]. Prabhakaran K, Arunachalam A, Sambathkumar R, et al. Development of fast dissolving tablets of sildenafil citrate for enhanced bioavailability. J Chem Pharm Res. 2010;2(6):147-156.

[143]. Pandey S, Paroha N, Dangi J, Mishra A, Giri S. Design and evaluation of fast dissolving tablets of sildenafil citrate. Int J Pharm Sci Res. 2012;3(9):2947-2951.

[144]. Patel M, Patel V, Patel B. Formulation and characterization of fast dissolving tablets of zolmitriptan. Int J Pharm Investig. 2012;2(3):134-138.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, November 2023

[145]. Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016;10:483-507.

[146]. Rane BR, Tiwari SS, Quadir AM, et al. In vitro and in vivo evaluation of fast dissolving tablets containing solid dispersion of pioglitazone hydrochloride. AAPS PharmSciTech. 2009;10(4):1251-1257.

[147]. Rajinikanth PS, Mishra B, Ekka N. Formulation, optimization and evaluation of fast dissolving tablets containing nebivolol hydrochloride using sublimation method. Digest J Nanomater Biostruct. 2010;5(2):359- 364.

[148]. Rao NS, Srinivas L. Formulation and evaluation of fast dissolving tablets of irbesartan. Asian J Pharm Clin Res. 2012;5(3):59-62.

[149]. Kumar A, Ahuja A, Ali J, Baboota S. Formulation and characterization of solid self-emulsifying drug delivery system of meloxicam for enhancement of dissolution rate. Int J Pharm Investig. 2011;1(4):206-215.

[150]. Kumar M, Sharma G, Shukla A, et al. A review on excipients used in oral disintegrating tablet. J Drug Deliv Ther. 2014;4(4):63-75.